Introduction

The Pulmonary Artery Pulsatility Index (PAPi) is a measure of right ventricular (RV) function derived from the pulmonary artery pressure waveform. PAPi has been increasingly used as a prognostic marker for patients with various cardiopulmonary diseases. In this article, we will discuss the significance of PAPi, its calculation, clinical utility, limitations, and future research directions.

Calculation

PAPi is calculated by dividing the difference between the systolic and diastolic pulmonary artery pressure by the mean pulmonary artery pressure.

PAPi = (systolic PAP – diastolic PAP) / mean PAP

Mean pulmonary artery pressure is calculated as diastolic PAP + 1/3 (systolic PAP – diastolic PAP).

PAPi can be measured invasively using a pulmonary artery catheter or non-invasively using echocardiography.

Clinical utility

PAPi is an indicator of RV afterload and function. A PAPi value of less than 1.0 indicates reduced right ventricular (RV) systolic function and is associated with increased morbidity and mortality in several conditions, such as pulmonary hypertension, acute respiratory distress syndrome (ARDS), and heart failure with preserved ejection fraction (HFpEF). Conversely, a PAPi value greater than 1.0 suggests preserved RV function and has been associated with better outcomes in patients with pulmonary hypertension and ARDS.

In patients with RV failure, PAPi is typically low due to increased RV afterload and impaired RV function. In contrast, in patients with normal RV function and low RV afterload, PAPi is typically high.

PAPi has been studied in various cardiopulmonary diseases, including acute respiratory distress syndrome (ARDS), pulmonary embolism, pulmonary hypertension, and heart failure:

• In patients with ARDS, low PAPi values are associated with increased mortality, longer duration of mechanical ventilation, and increased risk of barotrauma.
• In patients with pulmonary embolism, low PAPi values are associated with increased mortality, while high PAPI values are associated with a lower risk of mortality.
• In patients with pulmonary hypertension, PAPi is a useful predictor of response to vasodilator therapy.
• In patients with heart failure, low PAPi values are associated with increased mortality and morbidity.

Limitations

Although PAPi has shown promise as a prognostic marker, there are limitations to its use.

1. PAPi is highly dependent on accurate measurement of pulmonary artery pressures, which can be affected by various factors such as catheter positioning, respiratory variation, and patient position.
2. PAPI may not accurately reflect RV function in patients with RV hypertrophy or dilation, as these conditions can alter the shape of the pulmonary artery waveform.
3. PAPi does not take into account other factors that can influence RV function, such as RV contractility, heart rate, and preload.

Future research

Despite its limitations, PAPi remains a promising marker of RV function and prognosis in various cardiopulmonary diseases. Future research should focus on improving the accuracy and reproducibility of PAPi measurements, identifying the optimal cutoff values for various diseases, and determining the clinical utility of PAPi in guiding therapeutic interventions. Additionally, further studies are needed to investigate the impact of interventions that improve RV function, such as inhaled nitric oxide or mechanical ventilation strategies, on PAPi values and patient outcomes.

Conclusion

PAPi is a useful marker of RV function and prognosis in various cardiopulmonary diseases. It is calculated by dividing the difference between systolic and diastolic pulmonary artery pressures by mean pulmonary artery pressure. PAPi has limitations, including dependence on accurate measurement of pulmonary artery pressures and the inability to account for other factors that can influence RV function. Despite these limitations, PAPi remains a promising tool for guiding therapeutic interventions and predicting outcomes in patients with cardiopulmonary diseases.

References:

1. Chemla D, Hebert JL, Coirault C, et al. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. Am J Physiol. 1998;274(2 Pt 1):H500-H505. doi:10.1152/ajpheart.1998.274.2.H500
2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-975. doi:10.1183/13993003.01032-2015
3. Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017;9(413):eaao4583. doi:10.1126/scitranslmed.aao4583
4. Saouti N, Morshuis W, van den Bergh Weerman MA, et al. Non-invasive assessment of pulmonary artery pressure by Doppler echocardiography in connective tissue disease patients: a systematic review. Rheumatology (Oxford). 2013;52(6):1030-1042. doi:10.1093/rheumatology/kes420
5. Tedford RJ, Hassoun PM, Mathai SC, et al. Pulmonary arterial pulsatility index is associated with right ventricular failure in patients with pulmonary hypertension. Circulation. 2012;126(20):2563-2572. doi:10.1161/CIRCULATIONAHA.112.114066